BioNTech Cancer Drug Fails First Trial Endpoint
BioNTech said its BNT113 immunotherapy, combined with pembrolizumab, did not significantly improve progression-free survival at the first dual primary endpoint in a Phase 2/3 trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.